Cargando…

Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells

BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo prac...

Descripción completa

Detalles Bibliográficos
Autores principales: Konaka, Ken, Moriyama, Kota, Sakurada, Takumi, Okada, Naoto, Imanishi, Masaki, Zamami, Yoshito, Kawazoe, Kazuyoshi, Fushitani, Shuji, Ishizawa, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521132/
https://www.ncbi.nlm.nih.gov/pubmed/28748102
http://dx.doi.org/10.1186/s40780-017-0090-y
_version_ 1783251922993545216
author Konaka, Ken
Moriyama, Kota
Sakurada, Takumi
Okada, Naoto
Imanishi, Masaki
Zamami, Yoshito
Kawazoe, Kazuyoshi
Fushitani, Shuji
Ishizawa, Keisuke
author_facet Konaka, Ken
Moriyama, Kota
Sakurada, Takumi
Okada, Naoto
Imanishi, Masaki
Zamami, Yoshito
Kawazoe, Kazuyoshi
Fushitani, Shuji
Ishizawa, Keisuke
author_sort Konaka, Ken
collection PubMed
description BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto, and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy. METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo. We also compared phosphorylation of extracellular signal-regulated kinase (Erk)1/2 and Akt via Western blot analysis. About effect of kampo to anticancer efficacy, we confirmed cell cytotoxicity in A549 cells using MTT assay. RESULTS: Addition of Kamishoyosan or Shakuyakukanzoto, but not Goshajinkigan, significantly improved neurite length and GAP-43 and NF-L levels from paclitaxel-treated PC12 cells, relative to those of only NGF-treated PC12 cells. The promoting effect of Kamishoyosan and Shakuyakukanzoto in neurite outgrowth is confirmed when NGF promoted neurite outgrowth, and it was inhibited partially when Erk1/2 and Akt were blocked by Erk1/2 inhibitor or Akt inhibitor alone. Furthermore, neurite outgrowth induced by TJ24 and TJ68 was inhibited more strongly when Erk1/2 inhibitor and Akt inhibitor were treated at the same time. NGF with Kamishoyosan or Shakuyakukanzoto promoted the proportion of phosphorylated Erk1/2 and phosphorylated Akt compare with NGF only. On the other hand, Kamishoyosan or Shakuyakukanzoto didn’t influence cytotoxicity of paclitaxel in A549 cells. CONCLUSIONS: Kamishoyosan or Shakuyakukanzoto promotes neurite outgrowth with NGF via increasing the proportion of phosphorylated Erk1/2 and phosphorylated Akt in PC12 cells. The effect applies to recovery from paclitaxel-induced axonal involvement and might promote recovery from paclitaxel-induced neuropathy without influence of anticancer effect of paclitaxel.
format Online
Article
Text
id pubmed-5521132
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55211322017-07-26 Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells Konaka, Ken Moriyama, Kota Sakurada, Takumi Okada, Naoto Imanishi, Masaki Zamami, Yoshito Kawazoe, Kazuyoshi Fushitani, Shuji Ishizawa, Keisuke J Pharm Health Care Sci Research Article BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto, and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy. METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo. We also compared phosphorylation of extracellular signal-regulated kinase (Erk)1/2 and Akt via Western blot analysis. About effect of kampo to anticancer efficacy, we confirmed cell cytotoxicity in A549 cells using MTT assay. RESULTS: Addition of Kamishoyosan or Shakuyakukanzoto, but not Goshajinkigan, significantly improved neurite length and GAP-43 and NF-L levels from paclitaxel-treated PC12 cells, relative to those of only NGF-treated PC12 cells. The promoting effect of Kamishoyosan and Shakuyakukanzoto in neurite outgrowth is confirmed when NGF promoted neurite outgrowth, and it was inhibited partially when Erk1/2 and Akt were blocked by Erk1/2 inhibitor or Akt inhibitor alone. Furthermore, neurite outgrowth induced by TJ24 and TJ68 was inhibited more strongly when Erk1/2 inhibitor and Akt inhibitor were treated at the same time. NGF with Kamishoyosan or Shakuyakukanzoto promoted the proportion of phosphorylated Erk1/2 and phosphorylated Akt compare with NGF only. On the other hand, Kamishoyosan or Shakuyakukanzoto didn’t influence cytotoxicity of paclitaxel in A549 cells. CONCLUSIONS: Kamishoyosan or Shakuyakukanzoto promotes neurite outgrowth with NGF via increasing the proportion of phosphorylated Erk1/2 and phosphorylated Akt in PC12 cells. The effect applies to recovery from paclitaxel-induced axonal involvement and might promote recovery from paclitaxel-induced neuropathy without influence of anticancer effect of paclitaxel. BioMed Central 2017-07-21 /pmc/articles/PMC5521132/ /pubmed/28748102 http://dx.doi.org/10.1186/s40780-017-0090-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Konaka, Ken
Moriyama, Kota
Sakurada, Takumi
Okada, Naoto
Imanishi, Masaki
Zamami, Yoshito
Kawazoe, Kazuyoshi
Fushitani, Shuji
Ishizawa, Keisuke
Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
title Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
title_full Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
title_fullStr Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
title_full_unstemmed Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
title_short Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
title_sort kamishoyosan and shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in pc12 cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521132/
https://www.ncbi.nlm.nih.gov/pubmed/28748102
http://dx.doi.org/10.1186/s40780-017-0090-y
work_keys_str_mv AT konakaken kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT moriyamakota kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT sakuradatakumi kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT okadanaoto kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT imanishimasaki kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT zamamiyoshito kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT kawazoekazuyoshi kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT fushitanishuji kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells
AT ishizawakeisuke kamishoyosanandshakuyakukanzotopromoterecoveryfrompaclitaxelinducedneuriteretractioninpc12cells